為應(yīng)對(duì)未來的冠狀病毒威脅而開發(fā)的新型多合一疫苗
指南者留學(xué)
2022-07-06 11:14:14
閱讀量:1237
<div data-page-id="doxcnG10oM3yctCBUXfZqRgjQ7d" data-docx-has-block-data="true">
<div class="image-uploaded gallery old-record-id-doxcn6KOk66QK8YEKE3U5LvHgBf" style="text-align: justify;" data-type="image" data-ace-gallery-json="{"items":[{"uuid":"e4658f7c-18ac-4e9d-ac9d-55f2452a550b","height":575,"width":1200,"currHeight":575,"currWidth":1200,"natrualHeight":575,"natrualWidth":1200,"pluginName":"imageUpload","scale":1,"src":"https%3A%2F%2Finternal-api-drive-stream.feishu.cn%2Fspace%2Fapi%2Fbox%2Fstream%2Fdownload%2Fall%2FboxcnmJa2RS5LBdK4YJ0DedgPmc%2F%3Fmount_node_token%3Ddoxcn6KOk66QK8YEKE3U5LvHgBf%26mount_point%3Ddocx_image","file_token":"boxcnmJa2RS5LBdK4YJ0DedgPmc","image_type":"image/png","size":848157,"comments":[]}]}">
<div data-page-id="doxcnG10oM3yctCBUXfZqRgjQ7d" data-docx-has-block-data="true">
<div class="image-uploaded gallery old-record-id-doxcn6KOk66QK8YEKE3U5LvHgBf" style="text-align: justify;" data-type="image" data-ace-gallery-json="{"items":[{"uuid":"0d1380e4-5eb0-4b5a-9bb9-58e935b784e8","height":575,"width":1200,"currHeight":575,"currWidth":1200,"natrualHeight":575,"natrualWidth":1200,"pluginName":"imageUpload","scale":1,"src":"https%3A%2F%2Finternal-api-drive-stream.feishu.cn%2Fspace%2Fapi%2Fbox%2Fstream%2Fdownload%2Fall%2FboxcnmJa2RS5LBdK4YJ0DedgPmc%2F%3Fmount_node_token%3Ddoxcn6KOk66QK8YEKE3U5LvHgBf%26mount_point%3Ddocx_image","file_token":"boxcnmJa2RS5LBdK4YJ0DedgPmc","image_type":"image/png","size":848157,"comments":[]}]}"><img src="https://info.compassedu.hk/sucai/content/1657534657105/1657534657105.png" width="807" height="387" /></div>
</div>
</div>
<h2 class="heading-2 ace-line old-record-id-doxcnOkekSAkmsmm8iEhxVGFKIc" style="text-align: justify;"><strong><span class="p">流行病防范創(chuàng)新聯(lián)盟(CEPI)已宣布提供高達(dá)3000萬美元的資金,將一種新型納米顆粒疫苗用于臨床試驗(yàn),以提供對(duì)一系列冠狀病毒的保護(hù)。</span></strong></h2>
<p style="text-align: justify;"> </p>
<div class="ace-line ace-line old-record-id-doxcnMuYKekYCCmM4x12Tm2agGu" style="text-align: justify;">截至2022年7月,隨著SARS-CoV-2浪潮的不斷涌現(xiàn),不確定性仍然存在。隨著時(shí)間的推移,新的病毒變種出現(xiàn),并有可能減少現(xiàn)有疫苗工作的影響。顯然需要制定戰(zhàn)略,既要應(yīng)對(duì)新出現(xiàn)的變種,又要保護(hù)人群免受未來對(duì)人類健康的潛在威脅,例如相關(guān)的蝙蝠病毒。</div>
<div class="ace-line ace-line old-record-id-doxcnMuYKekYCCmM4x12Tm2agGu" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcn22QEmQM8QOgiaovi3RGszd" style="text-align: justify;"><a href="https://www.uk-cpi.com/news/cepi-funds-consortium-led-by-cpi-to-advance-caltechs-new-all-in-one-coronavirus-vaccine" target="_blank" rel="noopener">一個(gè)新的聯(lián)盟旨在通過為新的疫苗設(shè)計(jì)建立第一個(gè)人體臨床概念驗(yàn)證來解決這些問題。</a>該疫苗將針對(duì)SARS-CoV-2和一些有可能傳播給人類的相關(guān)蝙蝠病毒。它建立在牛津大學(xué)分子免疫學(xué)小組和加州理工學(xué)院比約克曼小組開發(fā)的技術(shù)之上 - 分別由MRC人體免疫學(xué)部門的<a href="https://www.rdm.ox.ac.uk/people/alain-townsend" target="_blank" rel="noopener">Alain Townsend教授</a>和Pamela Bjorkman教授領(lǐng)導(dǎo)。</div>
<div class="image-uploaded gallery old-record-id-doxcnWo0IYCuuCq0KGhaYxrYxeb" style="text-align: justify;" data-type="image" data-ace-gallery-json="{"items":[{"uuid":"cd1fd9ed-40ca-4982-bf25-0a932b78bed3","height":239.66480446927372,"width":194.99999999999997,"currHeight":239.66480446927372,"currWidth":194.99999999999997,"natrualHeight":220,"natrualWidth":179,"pluginName":"imageUpload","scale":1.089385474860335,"src":"https%3A%2F%2Finternal-api-drive-stream.feishu.cn%2Fspace%2Fapi%2Fbox%2Fstream%2Fdownload%2Fall%2Fboxcn5E6JQuBamt3idLFEoVcQ5y%2F%3Fmount_node_token%3DdoxcnWo0IYCuuCq0KGhaYxrYxeb%26mount_point%3Ddocx_image","file_token":"boxcn5E6JQuBamt3idLFEoVcQ5y","image_type":"image/jpeg","size":10029,"comments":[]}]}">
<div data-page-id="doxcnG10oM3yctCBUXfZqRgjQ7d" data-docx-has-block-data="true">
<div class="image-uploaded gallery old-record-id-doxcnWo0IYCuuCq0KGhaYxrYxeb" data-type="image" data-ace-gallery-json="{"items":[{"uuid":"0d54023d-855d-4eec-9f3e-70e1cc7ef06d","height":239.66480446927372,"width":194.99999999999997,"currHeight":239.66480446927372,"currWidth":194.99999999999997,"natrualHeight":220,"natrualWidth":179,"pluginName":"imageUpload","scale":1.089385474860335,"src":"https%3A%2F%2Finternal-api-drive-stream.feishu.cn%2Fspace%2Fapi%2Fbox%2Fstream%2Fdownload%2Fall%2Fboxcn5E6JQuBamt3idLFEoVcQ5y%2F%3Fmount_node_token%3DdoxcnWo0IYCuuCq0KGhaYxrYxeb%26mount_point%3Ddocx_image","file_token":"boxcn5E6JQuBamt3idLFEoVcQ5y","image_type":"image/jpeg","size":10029,"comments":[]}]}"><img style="display: block; margin-left: auto; margin-right: auto;" src="https://info.compassedu.hk/sucai/content/1657534662469/1657534662469.jpg" width="179" height="220" /></div>
</div>
</div>
<div class="ace-line ace-line old-record-id-doxcn42WWec28U8gEVe0lssBRcI" style="text-align: justify;">該聯(lián)盟匯集了牛津大學(xué)和加州理工學(xué)院的研究人員,與深度技術(shù)創(chuàng)新組織CPI和工業(yè)生物技術(shù)公司Ingenza Ltd(Caltech-CPI-Oxford-Ingenza)合作。</div>
<div class="ace-line ace-line old-record-id-doxcn42WWec28U8gEVe0lssBRcI" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcnG4wwSwSSQs2GCQoelUcjnt" style="text-align: justify;">流行病防范創(chuàng)新聯(lián)盟(CEPI)將與該聯(lián)盟合作,并宣布提供高達(dá)3000萬美元的資金,用于資助基于該技術(shù)的臨床前研究,GMP制造和1期試驗(yàn)。</div>
<div class="ace-line ace-line old-record-id-doxcnG4wwSwSSQs2GCQoelUcjnt" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcnWy0gYQEuWSMgOmu0QgLbYf" style="text-align: justify;">與許多使用mRNA或病毒載體將單一類型病毒的刺突蛋白片段呈現(xiàn)給免疫系統(tǒng)的現(xiàn)有疫苗設(shè)計(jì)相反,這種新疫苗將使用含有蛋白質(zhì)“膠水”的蛋白質(zhì)納米顆粒來附著來自八種不同病毒的刺突蛋白的相關(guān)抗原切片。通過結(jié)合加州理工學(xué)院創(chuàng)建的“mosaic-8疫苗”設(shè)計(jì),這些納米顆粒將有利于對(duì)單一疫苗中每種不同類型的冠狀病毒的共享部分的免疫反應(yīng)。</div>
<div class="ace-line ace-line old-record-id-doxcnWy0gYQEuWSMgOmu0QgLbYf" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcn2K8w0gKuWuq2kjuLg0TiBf" style="text-align: justify;">研究人員今天發(fā)表在《<em><a href="https://www.science.org/doi/10.1126/science.abq0839" target="_blank" rel="noopener">科學(xué)》雜志</a></em>上的證據(jù)顯示,這種疫苗技術(shù)不僅可以引發(fā)針對(duì)SARS樣病毒的保護(hù)性免疫反應(yīng),還可以針對(duì)試驗(yàn)疫苗中未出現(xiàn)的一些冠狀病毒。這表明該技術(shù)可以提供保護(hù),防止未來新的SARS-CoV-2變體和尚未發(fā)現(xiàn)的冠狀病毒,這些冠狀病毒有可能從動(dòng)物種群中溢出。</div>
<div class="ace-line ace-line old-record-id-doxcn2K8w0gKuWuq2kjuLg0TiBf" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcnA4KKsYqOeskqsFvCMTcHsb" style="text-align: justify;">該聯(lián)盟的牛津負(fù)責(zé)人,牛津大學(xué)MRC Weatherall分子醫(yī)學(xué)研究所分子免疫學(xué)教授Alain Townsend說:</div>
<div class="ace-line ace-line old-record-id-doxcnOAw8kg0cmeucczM7beBOeh" style="text-align: justify;">“這個(gè)聯(lián)盟的演變是合作科學(xué)最好的一個(gè)例子。馬克·豪沃思(Mark Howarth)(牛津大學(xué)生物化學(xué))開發(fā)的將蛋白質(zhì)粘在一起的“膠水”的力量給我們留下了深刻的印象,這種“膠水”來自他對(duì)<em>化膿性鏈球菌</em>細(xì)菌的美麗基礎(chǔ)科學(xué)研究。</div>
<div class="ace-line ace-line old-record-id-doxcnOAw8kg0cmeucczM7beBOeh" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcn6sEMs2egOYQ8cF99h7RpOe" style="text-align: justify;">“我們一起使用這項(xiàng)技術(shù)制造了一種原型納米顆粒SARS-CoV-2疫苗,該疫苗在臨床前研究中誘導(dǎo)了有效的反應(yīng)。</div>
<div class="ace-line ace-line old-record-id-doxcn6sEMs2egOYQ8cF99h7RpOe" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcni0GWG0YuQOmO47BYfhK2Pg" style="text-align: justify;">“通過Ian Wilkinson(絕對(duì)抗體)建立的聯(lián)系,我們與Ingenza和CPI的同事一起成功制造了微生物中生產(chǎn)的疫苗的全功能版本,從而降低了生產(chǎn)成本。我們一直在與Pamela Bjorkman教授和加州理工學(xué)院團(tuán)隊(duì)合作,他們獨(dú)立開發(fā)了馬賽克疫苗版本的精彩概念,并很高興繼續(xù)與這個(gè)世界級(jí)的聯(lián)盟合作。</div>
<div class="ace-line ace-line old-record-id-doxcni0GWG0YuQOmO47BYfhK2Pg" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcne2mAikuy8g62cfFrFZpidc" style="text-align: justify;">財(cái)團(tuán)合作伙伴致力于實(shí)現(xiàn)公平獲得項(xiàng)目產(chǎn)出。</div>
<div class="ace-line ace-line old-record-id-doxcne2mAikuy8g62cfFrFZpidc" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcnyCQQWsMGs60IOQNOSy70Pe" style="text-align: justify;">該聯(lián)盟的項(xiàng)目經(jīng)理(牛津大學(xué)),MRC Weatherall分子醫(yī)學(xué)研究所的高級(jí)博士后科學(xué)家<a href="https://www.rdm.ox.ac.uk/people/tiong-tan" target="_blank" rel="noopener">Jack Tan博士</a>說:</div>
<div class="ace-line ace-line old-record-id-doxcn2egEWWumQMqyqgFAOVN6bd" style="text-align: justify;">“我們很高興與CEPI合作,進(jìn)一步推進(jìn)這種納米顆粒技術(shù),目標(biāo)是生產(chǎn)有效,低成本,基礎(chǔ)設(shè)施獨(dú)立的疫苗,這些疫苗將可供低收入和中等收入國家使用。</div>
<div class="ace-line ace-line old-record-id-doxcn2egEWWumQMqyqgFAOVN6bd" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcnQwSEK88iCcOwGYuaAcOqIb" style="text-align: justify;">CEPI首席執(zhí)行官Richard Hatchett博士說:“21世紀(jì)已經(jīng)發(fā)生了三次嚴(yán)重的冠狀病毒流行病或大流行 - COVID-19繼續(xù)對(duì)世界的健康,社會(huì)和經(jīng)濟(jì)產(chǎn)生破壞性影響。創(chuàng)造能夠針對(duì)新出現(xiàn)的COVID-19變種和未來冠狀病毒威脅提供廣泛保護(hù)的疫苗不僅有助于減輕另一種類似COVID-19的大流行的破壞性影響,還有助于減少不斷更新疫苗配方所花費(fèi)的時(shí)間和資金。</div>
<div class="ace-line ace-line old-record-id-doxcnQwSEK88iCcOwGYuaAcOqIb" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcnmaigg8IQ88ISocb3Wdvip6" style="text-align: justify;">“這就是為什么我們很高興今天與這個(gè)由CPI領(lǐng)導(dǎo)的研究聯(lián)盟合作,以Wellcome Leap的初始投資為基礎(chǔ),進(jìn)一步推進(jìn)這種開創(chuàng)性的馬賽克納米顆粒疫苗技術(shù),如果成功,可以致力于將冠狀病毒構(gòu)成的威脅托付給歷史書。</div>
<div class="ace-line ace-line old-record-id-doxcnmaigg8IQ88ISocb3Wdvip6" style="text-align: justify;"> </div>
<div class="ace-line ace-line old-record-id-doxcne0kC6ugKyIqCu6YHx6zzmd" style="text-align: justify;">該聯(lián)盟的目標(biāo)是在2024年開始由牛津疫苗集團(tuán)領(lǐng)導(dǎo)的1期試驗(yàn)。</div>
</div>